文章摘要
葛怀廷,魏伟,李聪聪,曲立新.依达拉奉右莰醇对急性缺血性脑卒中患者神经功能及血清炎性因子的影响[J].药学与临床研究,2022,30(6):487~491
依达拉奉右莰醇对急性缺血性脑卒中患者神经功能及血清炎性因子的影响
Effects of Edaravone Dexborneol on Neurological Function and Serum Inflammatory Factors in Patients with Acute Ischemic Stroke
投稿时间:2022-08-01  修订日期:2022-12-18
DOI:
中文关键词: 急性缺血性脑卒中  依达拉奉右莰醇  阿替普酶  静脉溶栓  炎性因子
英文关键词: Acute ischemic stroke (AIS)  Edaravone dexborneol  Alteplase  Intravenous thrombolysis  Inflammatory factors
基金项目:山东省医药卫生科技发展计划项目(2017WS765)
作者单位邮编
葛怀廷 山东大学齐鲁医院德州医院神经内科 253000
魏伟 山东大学齐鲁医院德州医院神经内科 
李聪聪 山东大学齐鲁医院德州医院神经内科 
曲立新 山东大学齐鲁医院德州医院神经内科 253000
摘要点击次数: 505
全文下载次数: 333
中文摘要:
      目的:本研究探讨依达拉奉右莰醇对急性缺血性脑卒中(AIS)患者的神经功能及血清炎性因子的影响。方法:回顾性分析自2020年9月至2021年4月本院收治的197例AIS患者的临床资料。根据治疗方式,分为依达拉奉右莰醇组、常规治疗组、依达拉奉右莰醇联合阿替普酶组和阿替普酶组;疗程为10天。比较依达拉奉右莰醇组与常规治疗组,阿替普酶组与依达拉奉右莰醇联合阿替普酶组治疗前后NIHSS评分及炎性因子的变化。结果:4组患者治疗前的NIHSS评分及炎性因子水平无显著性差异。基线校正前,依达拉奉右莰醇联合阿替普酶组NIHSS评分,hs-CRP、TNF-α和IL-6下降数值最多;常规治疗组神经功能和各项炎性因子的前后下降程度都弱于其他组。两因素析因分析表明,相较于未使用依达拉奉右莰醇的治疗组(常规治疗组以及阿替普酶组),无论是否连用阿替普酶的情况下,使用依达拉奉右莰醇均能显著改善NIHSS评分,以及hs-CRP、TNF-α、IL-6炎性因子水平(P = 0.001)。基线校正后,结论依然成立。两两比较结果表明,依达拉奉右莰醇组联合阿替普酶组的NIHSS评分,hs-CRP、TNF-α、IL-6的下降数值均>阿替普酶组,且均具有统计学意义(P < 0.05);依达拉奉右莰醇组的NIHSS评分和各炎性因子的下降数值>常规治疗组,且差异具有统计学意义(P < 0.05); 依达拉奉右莰醇组与阿替普酶组之间的NIHSS评分的下降数值无统计学差异(P > 0.05)。结论:依达拉奉右莰醇能明显降低AIS患者的炎性因子水平,改善AIS患者的神经功能;依达拉奉右莰醇联合阿替普酶较阿替普酶单独治疗能显著改善AIS患者的神经功能。相较于未使用依达拉奉右莰醇的治疗,使用依达拉奉右莰醇治疗(无论是否联用阿替普酶)均能显著改善AIS患者的神经功能及炎性因子水平。
英文摘要:
      Objective: This study aimed to investigate the therapeutic effects of edaravone dexborneol on neurological functions and serum inflammatory factors in patients with acute ischemic stroke (AIS). Methods: The clinical data of 197 AIS patients admitted in our hospital from September 2020 to April 2021 were retrospectively analyzed. According to the treatment modality, those AIS patients were divided into edaravone dexborneol group, routine group, edaravone dexborneol combined with alteplase group and alteplase group. The treatment course was 10 days in this study. The changes of neurological functions and inflammatory factors were compared among the groups and before and after the treatments. Results: There were no significant differences in NIHSS scores and levels of hs-CRP, IL-6 and TNF-α among the four groups before the treatments. Before baseline correction, NIHSS scores and levels of hs-CRP, TNF-α and IL-6 decreased most after treatment in the edaravone dexborneol combined with alteplase group. Besides, the decreased values of NIHSS scores and serum inflammatory factors were less in the routine group than other groups. According to two-factor factorial design, edaravone dexborneol treatment could significantly decrease NIHSS scores and levels of hs-CRP, TNF-α and IL-6 (P = 0.001) regardless of alteplase use, compared with the groups without edaravone dexborneol treatment (routine group and alteplase group). In addition, the conclusions mentioned above remained valid after baseline correction. The results of pairwise comparison showed that NIHSS scores and levels of hs-CRP, TNF-α and IL-6 decreased more significantly in the edaravone dexborneol combined with alteplase group than the alteplase group (P < 0.05). In addition, NIHSS scores and levels of serum inflammatory factors in the edaravone dexborneol group were better improved than those in the routine group (P < 0.05). There was no significant difference in the decrease of NIHSS scores between the edaravone dexborneol group and alteplase group (P > 0.05). Conclusions: Edaravone dexborneol could significantly improve the neurological functions and reduce the levels of serum inflammatory factors in patients with AIS. Besides, edaravone dexborneol combined with alteplase led to better neurological function improvement than alteplase alone. Compared with treatment without edaravone dexborneol, treatment with edaravone dexborneol (with or without alteplase) significantly improved neurological functions and serum inflammatory factors in AIS patients.
查看全文   查看/发表评论  下载PDF阅读器
关闭